Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.

[1]  P. Ponikowski,et al.  In‐hospital worsening heart failure , 2015, European journal of heart failure.

[2]  K. Anstrom,et al.  Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). , 2015, Circulation. Heart failure.

[3]  K. Anstrom,et al.  Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights from DOSE-AHF and CARRESS-HF , 2015 .

[4]  P. Ponikowski,et al.  Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease , 2015, European journal of heart failure.

[5]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[6]  K. Anstrom,et al.  DECONGESTION STRATEGIES AND RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ACTIVATION IN ACUTE HEART FAILURE , 2014 .

[7]  W. Tang,et al.  Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: a single-center experience. , 2014, Journal of cardiac failure.

[8]  P. Ponikowski,et al.  Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial , 2013, European heart journal.

[9]  K. Swedberg,et al.  Serum aldosterone is associated with mortality and re‐hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial , 2013, European journal of heart failure.

[10]  V. Hasselblad,et al.  Predictors of early dyspnoea relief in acute heart failure and the association with 30‐day outcomes: findings from ASCEND‐HF , 2013, European journal of heart failure.

[11]  B. Massie,et al.  Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. , 2013, JACC. Heart failure.

[12]  K. Swedberg,et al.  Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. , 2013, European heart journal.

[13]  K. Weber,et al.  Mineralocorticoid Receptor Antagonism Confers Cardioprotection in Heart Failure , 2013, Current Heart Failure Reports.

[14]  M. Vaduganathan,et al.  The disconnect between phase II and phase III trials of drugs for heart failure , 2013, Nature Reviews Cardiology.

[15]  R. Schrier,et al.  Increased Spironolactone in Advanced Heart Failure: Effect of Doses Greater than 25 mg/Day on Plasma Potassium Concentration , 2013, Cardiorenal Medicine.

[16]  Robert O. Bonow,et al.  Rehospitalization for heart failure: problems and perspectives. , 2013, Journal of the American College of Cardiology.

[17]  K. Anstrom,et al.  Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.

[18]  P. Kolkhof,et al.  Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics , 2012, Molecular and Cellular Endocrinology.

[19]  S. Normand,et al.  Abstract 13840: National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries: 1998-2008 , 2011 .

[20]  Mark D. Huffman,et al.  Executive Summary: Heart Disease and Stroke Statistics—2015 Update A Report From the American Heart Association , 2011, Circulation.

[21]  A. Azevedo,et al.  BNP at discharge in acute heart failure patients: is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status. , 2010, International journal of cardiology.

[22]  P. Ponikowski,et al.  Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.

[23]  P. Ponikowski,et al.  Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward , 2010, Circulation. Heart failure.

[24]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[25]  C. O'connor,et al.  Early worsening heart failure in patients admitted with acute heart failure – a new outcome measure associated with long‐term prognosis? , 2009, Fundamental & clinical pharmacology.

[26]  S. Normand,et al.  Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission , 2009, Circulation. Cardiovascular quality and outcomes.

[27]  R. Schrier,et al.  Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist? , 2009, Circulation. Heart failure.

[28]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[29]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[30]  R. Califf,et al.  Value of Clinician Assessment of Hemodynamics in Advanced Heart Failure: The ESCAPE Trial , 2008, Circulation. Heart failure.

[31]  D. Logeart,et al.  Transient worsening of renal function during hospitalization for acute heart failure alters outcome. , 2008, International journal of cardiology.

[32]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[33]  Karen A. Hartman,et al.  Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial. , 2007, Journal of cardiac failure.

[34]  G. Filippatos,et al.  Reassessing treatment of acute heart failure syndromes: the ADHERE Registry , 2005 .

[35]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[36]  Christopher M O'Connor,et al.  Risk stratification after hospitalization for decompensated heart failure. , 2004, Journal of cardiac failure.

[37]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[38]  I. Squire,et al.  Pre‐discharge, but not admission, levels of NT‐proBNP predict adverse prognosis following acute LVF , 2003, European journal of heart failure.

[39]  D. Ellison,et al.  Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. , 2001, Journal of the American Society of Nephrology : JASN.

[40]  J. Schafer.  Multiple imputation: a primer , 1999, Statistical methods in medical research.

[41]  L Goldman,et al.  Correlates of early hospital readmission or death in patients with congestive heart failure. , 1997, The American journal of cardiology.

[42]  A. Donker,et al.  Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. , 1993, The American journal of cardiology.

[43]  J. Ferreira,et al.  Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. , 2014, European journal of internal medicine.

[44]  D. Mozaffarian,et al.  Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[45]  D. Sica.  Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis , 2005, Heart Failure Reviews.

[46]  B. Pitt.  Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). , 1996, The American journal of cardiology.

[47]  W. Abraham,et al.  Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. , 1991, American journal of nephrology.